Pharmaceutical contract manufacturing and API sourcing: why not Central Europe?

3 August 2011

At present, only a few companies based in Central Europe and the Balkans emphasize their contract manufacturing and active pharmaceutical ingredients (API) sourcing services. There is relatively strong competition from companies from the Far East and from Western Europe.

On the other hand, the potential of the region seems to be considerable, with Poland and the Czech Republic still the most attractive locations, according to the latest report from Poland-based PMR, a research and consulting company, titled Pharmaceutical contract manufacturing and API sourcing in Central Europe and the Balkan states 2011.

Higher production costs matched by higher quality

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >